Introduction
For over 70% of patients with an inflamed or cancerous pancreas, the precipitating complaint is likely to be abdominal pain that can become severe and intractable. In fact, pancreatic cancer and chronic pancreatitis are among those syndromes characterized as causing the worst pain. Unfortunately, pancreatic cancer, which remains the fourth leading cause of cancer deaths in the United States, is almost always detected at late stage. However, life expectancy after diagnosis of pancreatic cancer has increased from months to years with better palliative treatments.
Pancreatic cancer is often preceded by acute and/or chronic pancreatitis conditions. Pancreatitis in the majority of cases occurs after prolonged alcohol consumption. However, the precipitating cause for development of pancreatitis in some but not all who abuse alcohol is unknown. In addition to alcohol abuse, other predisposing factors make the pancreas susceptible to inflammation, including genetics, smoking, high-fat diets, infections and a compromised immune system (US Department of Health and Human Services, National Institute on Alcohol Abuse and Alcoholism, 2003) . Idiopathic pancreatitis is reported in only 15% of cases. Over 50% of patients with idiopathic and alcoholic pancreatitis report chronic pain and for many of these patients the pain becomes debilitating. Chronic abdominal pain from the pancreas has significant negative impact on patient quality of life and mortality as it profoundly decreases appetite, leading to weight loss. When patients lose X20% of lean body mass, host immunocompetence becomes an issue.
The current treatment of pain in pancreatic cancer and chronic pancreatitis includes parenteral narcotic agents, surgical intervention at the level of pancreas or neural pathways and complementary therapies. Opiate treatment remains the primary nonsurgical mean in managing pancreatic pain. Use of narcotic agents is not optimal as there are risks of tolerance, addiction and intolerable side effects of sedation, constipation and nausea. Surgical intervention is invasive often resulting in transient or suboptimal relief of pain and may be therapeutically inappropriate based on the clinical status of the patient. Celiac plexus neurolysis is a currently accepted clinical treatment for severe intractable abdominal pain in abdominal malignancies and chronic pancreatitis usually reserved for patients who have failed other treatment modalities. The reported first year success rate for pain relief is reported between 57 and 100%, based on the approach and ethanol concentration. [1] [2] [3] [4] The effectiveness of blocks or sectioning of the sympathetic innervation, but not the vagus, indicates that afferent nerve fibers traveling with the sympathetic nerves are involved in transmitting nociceptive information from the pancreas. [5] [6] [7] [8] [9] [10] [11] Although generally well tolerated, reported complications after celiac plexus block include back pain, hypotension and diarrhea. 12, 13 Celiac plexus neurolysis essentially scleroses the nerve and blocks the afferent and efferent transmission of all neurochemicals. Neural blockade of a significant part of the enteric sympathetic nervous system in an otherwise functioning enteric system may lead to pancreatic or enteric pathologies, as the sympathetic nervous system has a vital function in modulating intestinal secretory and absorptive processes. This may become more of an issue with the improved cancer treatments and longer lifespan for patients with pancreatic malignancies.
Pancreatitis is also characterized by severe histopathological and inflammatory changes, such as the presence of inflammatory mediators, acinar atrophy, fat necrosis, intraductal hemorrhage, periductal fibrosis and stromal proliferation.
14 Elevated serum a-amylase, lipase and C-reactive protein levels serve as biochemical markers of acute pancreatitis. 15, 16 Acute pancreatitis ranges from mild edematous conditions that usually heal without intervention to severe hemorrhagic necrotizing inflammation that is often fatal over a period of days as patients succumb to abdominal sepsis and multiorgan failure. 17 The level of pain experienced by these patients is directly linked to the decreased pancreatic functioning and increased length of stay during hospitalizations. The pain is usually epigastric in nature and may radiate to the right and/or left upper quadrant and the back. 5 Mechanical and thermal thresholds in these areas are decreased. 18, 19 Many times pancreatitis lapses into a chronic condition and a lifetime of increasing pain that becomes resistant to opiates. In patient surveys, 32% of patients in chronic pancreatitis pain report being willing to try any new therapy for relief, and some may resort to suicide for this intractable pain state. Thus, the need to develop better therapeutic approaches by pursuing novel pain relief strategies remains high for patients with pancreatitis and pancreatic cancer.
One approach under study is use of viral vectors for delivery of agents providing pain relief. As patient survival is becoming a fortunate reality, consideration of route of administration for viral constructs should be a part of investigative preclinical studies. Viral vectors engineered for prolonged release of therapeutic agents could be administered to celiac ganglia in patients by anesthesiologists during routine endoscopic assessments. Herpes simplex virus (HSV)-1-based viral vectors could be given during serial ERCP clinical assessments (endoscopic retrograde cholangiopancreatography, a procedure used to assess progress of pancreatic disease). Alternatively, high levels of overexpressed agents could be obtained if viral vectors are delivered directly to the pancreas of patients through the stomach wall. This would allow site-specific uptake of the vector and delivery by axonal transport through the nerves innervating the pancreas to the dorsal root ganglia (DRG) of those nerves. After overexpression of pain-relieving molecules by the DRG, the axons would return the gene product directly to the pancreas in nerve terminals innervating the pancreas, as well as to those areas in the spinal cord directly involved in transmission of pancreatic pain. Viral vector delivery of opioids and other pain relief molecules directly to the pancreas, or other visceral organs, avoids first pass reduction of effective dose and spares patients from somnolence, diminished mental capacities, constipation and other systemic complications encountered with systemic delivery of morphine derivatives. This potential treatment would also be nerve plexus sparing and avoid the severe complications of pancreatic duct disruption encountered by endoscopists, including pancreatic insufficiency and enteric damage.
met-Enkephalin overexpression by HSV-Enk treatment in animal models of pancreatitis
The aim of two recent studies using animal pancreatitis models was to test innovative preclinical, site-specific gene therapeutic interventions. 20, 21 The efficacy of preand posttreatment with a replication defective herpes (HSV-1, DPE) viral vector construct encoding human preproenkephalin gene (HSV-Enk) to bring overexpressed opioids directly to pancreatic tissue was tested. In our studies, we examined the overexpressed metenkephalin generated by the HSV viral vector. Reduced pain-related behaviors, inflammatory and cellular activation responses in rats with acute and chronic pancreatitis were demonstrated after direct injection of the viral vector into the pancreas by laparotomy (Figure 1 ). Comparisons were made to sham and pancreatitis animals receiving vehicle or the neutral control b-galactosidase expressing virus (HSV-b-gal). The neurotropic HSV viral vectors are readily taken up by nerve endings in the pancreas and transported up the axons to the DRG. The HSV generates the gene product, metenkephalin, but not viral proteins in the DRG. Overexpressed met-enkephalin is transported both to the central and to the peripheral nerve terminal endings in the spinal cord dorsal horn and the pancreas, respectively. 22 Antihyperalgesic behavioral effects of met-enkephalin overexpression A hypersensitive nociceptive state was induced in rats in both animal models allowing us to test for reduction of visceral pain-related behaviors after treatment with the viral vector. With the acute chemically induced pancreatitis, animals received a tail vein injection of the industrial plasticizer (dibutyltin dichloride, DBTC) and Gene therapy for pancreatitis pain KN Westlund viral vector injections directly onto the surface of the pancreas just under the adhered peritoneal membrane (2 Â 10 6 plaque-forming units). 20 The exploratory behaviors assessed in the sham control animals indicated activity levels typical for rats in a 30-min testing period ( Figure 2a ). This included the number of xyz plane light beams broken in the light grid within the testing enclosure as the rats explored the enclosure in a darkened room (San Diego open-field testing unit). The exploratory behavior was significantly reduced in animals in the control groups with pancreatitis (DBTC with vehicle and DBTC with control HSV-b-gal vector). In comparison, the pain-related decrease in exploratory behavior was abrogated 1 week after inoculation of the viral vector, providing overexpression of preproenkephalin gene products. Pain-related behavior persisted, however, if HSV-Enk-treated animals were also given the opioid antagonist, naloxone. The naloxone was given intrathecally in the lower thoracic spinal cord (10 mg naloxone methiodide in 10 ml artificial cerebrospinal fluid according to Rohde et al. 23 ). Naloxone reversibility indicates the HSV-Enk overexpression effect restoring exploratory behavior was opioid mediated. Because the naloxone methiodide compound used in these open-field testing studies does not readily escape the blood-brain barrier, these data suggest that opioid receptors in the spinal cord can modulate transmission of visceral pain information to higher centers involved in processing affective responses to visceral pain. Similar results were observed for spinal naloxone methiodide in a model of bladder pain. 24 In studies using somatic pain models in which naloxone compounds were used that cross the blood-brain barrier, peripheral administration has also reversed HSV-Enk gene therapy effects. 25, 26 With a second model, in animals chronically fed a high-fat and alcohol diet to induce pancreatitis, nociceptive behavior was detected with hot-plate testing after 3 weeks on the diet. 21 With the hot-plate test the animals freely move about an enclosed area where the floor surface is maintained at 50 1C. The time until the animals produce an abnormal behavioral response (response time) is recorded. An abnormal purposeful avoidance response might include hindpaw flicking, licking, jumping, freezing and so on. After a purposeful response is made, animals are removed immediately from the testing area to avoid distress. Hot-plate sensitivity was reduced by the met-enkephalin overexpression for 4-6 weeks without development of tolerance to the overexpressed met-enkephalin (Figure 2b ). The persistence of the effect with this vector-mediated expression of proenkephalin gene products has been shown in the face of morphine tolerance in a neuropathic pain model. 26 Outright spontaneous pain behaviors were not evident in either of the animal models of pancreatitis pain. The methods used to evaluate pain-related behavior in these pancreatic models test whole body responses to the visceral pain rather than testing cutaneous hypersensitivity that develops at or near the site of injury in animal Diet/Vehicle (6) Diet/HSV-β-gal (7) Diet/HSV-ENK (7) Naive (3)
Hotplate test of thermal sensitivity for naive rats or rats with pancreatitis given either vehicle, HSV-ENK, or HSV-β-gal treatment. *p ≤ 0.05, vs Day0 (Mann Whitney U test); +p ≤ 0.05, Diet/HSV-ENK group vs Diet/Vehicle (Mann Whitney U test).
RESPONSE TIME (S) Chronic pancreatitis. Hot-plate response latency measurements are shown for naive animals and for the groups of animals fed chronically with the alcohol and high-fat diet. Hot-plate test was conducted at baseline before induction of pancreatitis and for 10 weeks subsequently. Note the significant shortening of hot-plate response latencies for rats on the high-fat and alcohol diet after week 3, indicating sensitization. The HSV-Enk treatment (given at 3 weeks) significantly abrogated the shift in response latency for at least 4 weeks. Four weeks is also typical of HSV vector expression before latency of the virus. Visceral pain in patients also produces diffuse, whole body sensitivity as well as affective responses, consistent with central sensitization.
28,29
Localization of met-enkephalin overexpression
The viral vector taken up by nerve endings in the pancreas was visualized as human HSV protein in the DRG only at the levels that innervate the pancreas in these animals (T8-T12; Figure 3A) . Likewise, an increase in met-enkephalin peptide was seen expressed in higher levels in the same DRG ( Figure 3B ). We determined that HSV-Enk produced met-enkephalin overexpression is also evident in pancreatic tissue in the periphery where it can be visualized with immunocytochemistry ( Figure  4A ), but no human HSV protein could be detected in the pancreas 6 weeks after the injections. An increase in metenkephalin was visualized at the central terminals of afferent nerves in the spinal cord dorsal horn at the levels innervating the pancreas (T8-T12; Figure 4B ). Thus, although met-enkephalin is typically degraded rapidly by endopeptidases within seconds in intracellular spaces, the nerve terminal content appears to provide a physiologically relevant format for delivery of metenkephalin to spinal cord centrally in the pancreas peripherally. The staining density in pancreatic acinar cells did not allow visualization of afferent nerve terminals in the pancreas. The combined effect of the central and peripheral met-enkephalin is likely responsible for effectively reducing the pain-related nociceptive behaviors (Figures 2a and b) .
Anti-inflammatory effects and tissue protection by HSV-Enk treatment
Surprisingly, the inflammation itself in the pancreas ( Figure 5A ) was also eliminated using the targeted gene therapeutic approach for overexpression of the endogenous opiate, met-enkephalin. 20, 21 Invading inflammatory cells readily stain for RANTES (regulated on activation, normal T-cell expressed and secreted chemokine) in the pancreas of control animals with the alcohol-induced pancreatitis with and without with neutral viral vector injections, but were not observed in pancreas of the HSVEnk-treated animals. Further, significant tissue preservation was noted in animals receiving the met-enkephalin overexpression vector. Hematoxylin and eosin stained sections reveal relatively normal histological preservation compared to control animals with pancreatitis ( Figure 5B ).
Opioid receptors are constitutively expressed in nonneuronal sites including on immune cells such as macrophages and lymphocytes, 30 on vascular endothelial cells 31, 32 and on keratinocytes. 33 We have shown, as have others, that m-opioid receptors are localized in the pancreas, and they no doubt have a function in the protection provided by the opioids generated by Gene therapy for pancreatitis pain KN Westlund the overexpression vector. 20 A primary function for opiates has been shown for reduction of inflammation through actions on m-and d-opioid receptors of the infiltrating inflammatory cells. m-(morphine), k-(U50488H) and d-2 (deltorphin II), but not d-1 (DPDPE) opioid agonists have been shown to produce dosedependent immunosuppressive effects on a plaqueforming assay, effects that were blocked by respective selective opioid antagonists. 34, 35 Furthermore, met-enkephalin has an immunoregulatory function through a naloxone reversible inhibition of immunoglobulin G 34 and protection from chemotaxis. 36 It is also well known that long-term administration of morphine reduces immune function through reduced hypothalamic-pituitary-adrenal axis activation.
It has been shown that the spinal cord can regulate peripheral inflammation through a variety of dorsal horn receptor mechanisms and dorsal root reflex primary afferent nerve activity. [37] [38] [39] [40] [41] [42] These actions were shown to occur through glutamate, GABA, substance P and adenosine receptor mechanisms. More recent studies have been carried out with spinal and intrathecal administration of opioid agents that influence these same receptors. 43 It is very likely that the overexpressed met-enkephalin we find in the spinal cord dorsal horn after preproenkephalin gene therapy has a function in the decreased inflammation observed in the pancreatitis.
Much less well studied is the report that m-opiates can directly reduce plasma extravasation by 24-36%. [44] [45] [46] [47] [48] [49] The local administration of m-and d-opioid receptor agonists, at doses that show no systemic effect, has been shown to decrease plasma extravasation during peripheral inflammation. 45 These effects are induced by activation of opioid receptors located in both the central and peripheral nervous systems. In the periphery, opioid receptors are expressed on a significant proportion of capsaicin sensitive sensory fibers and sympathetic postganglionic terminals, where they may participate in the modulation of nociceptive information under certain pathological conditions. 50 The reversibility of the effects induced by the opioid receptor agonists (edema and extravasation) has been established after the administration of antagonists (i.p.). 51 The work of Lei and Rogers Gene therapy for pancreatitis pain KN Westlund opioid receptors located on both sensory fibers and immune cells are selectively activated by low (neuronal) or high (non-neuronal) doses of m-and d-opioid receptor agonists. It is likely that a similar mechanism is reducing edema and tissue disruption in the HSV-Enk-treated animals where enkephalin is being released directly into the pancreas. However, a function(s) for m-opioid receptors located extraneuronally in peripheral tissue, as in the pancreas tissue in our DBTC pancreatitis model, has not been fully established. 20 Both the reduction in inflammation and tissue damage, as well as the effect of increasing enkephalins in the pancreas and spinal cord on neuronal activity, are providing reduction of the pain-related behaviors in our pancreatitis models. 20, 21 Equivalent findings for reduction of pain-related behaviors, tissue damage and decreased inflammation with use of similar HSV preproenkephalin overexpression vectors are reported for cutaneous and knee joint pain models. 20, 22, 53, 54 Released enkephalins have been measured in the spinal cord and skin using the same HSV-preproenkephalin vector injected cutaneously in rats and monkeys. 26, 54 It is known that enkephalin directly inhibits neurotransmitter release, including substance P, from presynaptic nerve terminals in both the central and peripheral nervous systems, 55 through a calcium channel blocking action. 56 Thus, met-enkephalin is capable of directly reducing pain-related neurotransmitter release and reducing inflammation through these mechanisms. The month-long duration of the antihyperalgesic effect and the profound tissue preservation seen after a single administration in these studies implies that infusions of viral vectors directly into the pancreas and other sites may provide prolonged site-specific relief from chronic pain and tissue protection from inflammatory responses for patients with use of clinically approved vectors.
Comparison of viral vectors for analgesic and anti-inflammatory potential
There are several inherent advantages to using HSVbased viral constructs for foreign gene delivery in certain clinical settings, rather than other viral delivery models under study. In the HSV vector, the inserted genes are under the control of a strong constitutive human cytomegalovirus promoter, which allows expression of inserted gene product at an intracellular locale, in the absence of productive HSV-1 infection and without integration into the host genome. 53 The recombinant viral vectors designed for gene therapy rendered replication conditional or defective do not produce productive viral infection in vivo, but can persist for months despite negligible viral protein synthesis. These viral constructs establish a quiescent state similar to natural viral latency but do not reactivate to cause active infection in neuronal cells in vivo.
53,57 HSV-1 viral constructs offer unique advantages in peripheral inflammation, as they selectively infect primary sensory neurons but do not integrate into the host genome. Thus, they will act as an independent 'minipump' source for protein synthesis in the neuronal cytoplasm. These are very important properties of HSV-1-based viral vectors, as 70-90% of the human adult population has evidence of prior HSV-1 infection. This limited potential to generate a host response also improves the potential Gene therapy for pancreatitis pain KN Westlund for using repeated doses of HSV-based viral constructs. Adenoviruses cause productive infection, induce host inflammation above the inflammation already generated in target tissues and increase potential for extended injury and host innate immune response to the virus making repeated doses problematic. 58 These adverse reactions are avoided with HSV viral vectors.
Thus, local injection of HSV-1 viral constructs with human proenkephalin gene insert results in targeted tissue expression of opioid protein, 54 whereas systemic administration of opiate compounds often has undesirable or intolerable side effects. 59 HSV-1 gene delivery and local opioid expression may potentiate exogenously administered morphine, lowering doses needed and delaying morphine tolerance. 60 This has been demonstrated in another HSV-based gene therapy model, where HSV viral vector infections potentiated chemotherapy agents in lung cancer 61 and breast cancer. 62 Attenuated HSVs have already been successfully used in Phase I/II trials for treatment of central nervous system (CNS) glioblastoma without apparent nonspecific toxic effects. 63, 64 The efficacy and potency of peripheral opioid effects are generally enhanced when drugs are administered during active inflammatory conditions.
65-69
Development of opiate tolerance?
Long-term treatment with systemic opiates is commonly prescribed for pain control for patients with pancreatic cancer and chronic pancreatitis. Morphine is known to release anti-nociceptive neuropeptide, met-enkephalin, in the spinal cord. 70 Repeated administration of exogenous opiates, such as morphine, however, frequently lead to tolerance, that is, reduced effectiveness. This is observed both in patients and in experimental animals. 71 In animal studies, tolerance to the exogenous opiate, morphine, can occur within 3-5 days depending upon the experimental stressor and method of morphine administration. Tolerance to morphine demonstrated with several stress paradigms (hindpaw compression, applied heat and cold water swim) coincides with decreased internalization of receptors for substance P, a natural peptide know also to be involved in pain processing. 72 Morphine tolerance has been prevented in studies blocking N-methyl-D-aspartate, substance P and calcitonin gene-related peptide receptors. 73, 74 Clearly, spinal cord neurotransmitter levels are important in the development of tolerance to exogenous opiates.
In the chronic pancreatitis study, the effectiveness of the overexpressed endogenous opioids neuropeptides in reduction of pain-related behavior was maintained for over an extended period of time (Figure 2b ). This indicates to us that overexpression of the endogenous proenkephalin products (leu-and met-enkephalin) in the HSV-Enk treated animals are sufficient to abrogate the effects of the pancreatitis without tolerance to the overexpressed endogenous opioids. The anti-nociceptive effects with this method of opiate delivery persist for over 4 weeks, the expected time frame for expression before latency of the virus. Thus, the important issue of desensitization and tolerance appears to be a nonissue with enkephalin generated by the HSV-Enk viral vector. In another chronic neuropathic pain study, the preproenkephalin vector not only reduced heat stress responses in animals with nerve ligations but also independently prevented morphine tolerance effects. 75 Furthermore, this study showed that the preproenkephalin overexpression can reduce effects of naloxone-induced morphine withdrawal. It is likely that the presence of high levels of met-enkephalin in the spinal cord seen in our animals receiving HSV-Enk ( Figure 4B ) is important in reduction of morphine tolerance as proposed in related studies by Trujillo et al. 76 It is known that rats with exogenous morphine-induced tolerance behaviors have decreased spinal and striatal preproenkephalin and met-enkephalin. 77, 78 Although the precise mechanisms allowing the protracted effectiveness of the endogenous opioids are not known at this time, we propose that it is the available, continuous release of overexpressed metenkephalin directly onto receptors at nerve terminals both centrally and peripherally (Figure 4 ) that provides additive effectiveness for reducing hyperalgesia and tissue protection from inflammatory responses without tolerance. In this site-directed manner, physiologically relevant levels of enkephalin can affect the very same afferent nerve fibers that receive information from the pancreas. Standard therapies relying on higher and higher levels of circulating exogenous opiates, on the other hand, frequently result in decreased spinal metenkephalin, intolerable side effects and development of tolerance.
Testing safety and efficacy issues
Our preclinical studies suggest that met-enkephalin gene therapy would offer a safe, site-directed, effective, welltolerated and advantageous approach for treatment of chronic pancreatic pain in patients. Although we have demonstrated evidence of HSV-1 in the DRG, the preferred host cell for HSV ( Figure 3A) , no CNS infection was found. 20, 21, 79 Likewise, viral protein was not found in pancreas, liver, lung, bladder, colon or spinal cord. Safety and efficacy of replication defective HSV vectors have already been demonstrated for other purposes in Phase I/II clinical trials. [79] [80] [81] [82] [83] [84] Replication-deficient virus has been used safely without spread when injected directly into brain as treatment for glioblastoma. 63, 64, 84 Owing to the success of opioid gene therapy we have described in recent published studies for rats with pancreatitis, 20, 21 continued efficacy and safety testing of HSV viral vector therapies for patient use is warranted.
Conclusions
Our studies have utilized pancreatitis models to establish rationale for use of HSV-based gene therapy for chronic visceral pain. These data imply significant translational relevance for preproenkephalin as a gene therapeutic agent, in particular. Targeted enkephalin therapy not only provides an innovative means of significantly reducing pancreatic pain sensitivity but may also restore pancreatic function by reducing pancreatic inflammation and preserving tissue architecture. The proposed gene therapy approach is providing clear promise for pain control for clinical pancreatitis and pancreatic cancer pain.
Because the large HSV cassette offers great potential for simultaneous delivery of multiple other gene Gene therapy for pancreatitis pain KN Westlund products, this approach might also be expanded in the future to deliver other gene products along with enkephalin to prolong and improve the impact upon pain, inflammation and structural integrity of tissues in these and other clinic patients. Further improvement of vector system design may provide other anti-inflammatory gene products to protect and restore functional integrity of damaged tissues long term. Gene therapy using HSV vectors for gene product delivery for intractable pain may be clinically preferred in patients with prospects of longer life spans and may improve functionality for patients with chronic nonmalignant pancreatitis.
